Navigation Links
MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study
Date:2/21/2008

other delivery forms including competing film products. MonoSol Rx's intellectual property includes thin film producing polymers, drug taste masking, processes that ensure product and content uniformity at scale, novel packaging and in-process testing methods.

Mr. Schobel continued, "The strength of our pipeline and intellectually property, combined with the convenience and potential dosing benefits of our thin film technology, sets MonoSol Rx apart as an innovator in the drug delivery sector. As the pharmaceutical industry evolves and more blockbuster drugs transition to generic, MonoSol Rx's objective is to leverage our thin film technology via partnerships and self-funded development initiatives to bring new products to market that enhance the effectiveness and market-appeal of already-approved compounds. We believe this strategy will enable MonoSol Rx to cement its leadership position in the thin film drug delivery market."

MonoSol Rx has signed a term sheet and is in final negotiations with a partner to market its thin film formulations for ondansetron in 4 and 8 mg strengths. Negotiations are expected to conclude prior to global regulatory submissions.

Keith Kendall, chief financial officer for MonoSol Rx, commented, "Completing an agreement with a partner for our ondansetron formulation should further solidify the market potential of MonoSol Rx's technology and continue to demonstrate our ability to develop and manufacture prescription thin film products at scale for our partners. This agreement would build upon the development and supply agreement that we signed with Adams Respiratory Therapeutics in March 2007 for another, as-yet-unnamed prescription product."

With an annual prescription market of $1.2 billion in the US and approx $100 million in the top-five European countries, ondansetron is recognized as the leading 5-HT3 antagonist used in the prevention and treatment of nausea and vomiting.

About MonoSol Rx

Mo
'/>"/>

SOURCE MonoSol Rx
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... YORK , Nov. 20, 2014  Market research firm ... the "Year of The Buy, in the medical device ... for medical devices will produce just 3% growth this ... actions, including acquisitions of product lines and entrance by ... annual survey of medical devices, The Global Market ...
(Date:11/21/2014)... SUNNYVALE, Calif. , Nov. 20, 2014 /PRNewswire/ ... Study at the 2014 AAGL Global Congress demonstrates ... vaginal insert designed to provide bowel control. One of ... MD, Associate Professor and Division Chief of Urogynecology ... North Carolina, won an Award for Best Written ...
(Date:11/21/2014)... BEVERLY HILLS, Calif. , Nov. 20, 2014 ... Ken Eaton , the election of Anthony J. ... as President. Effective November 19, 2014, ... and member of the Board of Directors of Oxis International, ... J. Cataldo has been named Chief Executive Officer of ...
Breaking Medicine Technology:Kalorama: 2014 The "Year of The Buy" in Medical Device Industry 2LIFE Study Prominently Featured at Minimally Invasive Gynecology Conference 2LIFE Study Prominently Featured at Minimally Invasive Gynecology Conference 3OXIS International, Inc. announces Changes in Management Team 2OXIS International, Inc. announces Changes in Management Team 3
(Date:11/21/2014)... 21, 2014 M3 Global Research , ... professional panel, today announced two important leadership changes to help ... as President of Market Research, Americas and the promotion of ... , Ms. DasGupta joined M3 in 2011 and has ... Head of Sales. Roni has over 17 years of ...
(Date:11/21/2014)... HealthDay Reporter THURSDAY, Nov. 20, ... pregnant are much more likely to have a child who ... But it looks like environment may play a greater ... "Mothers who are overweight teach behaviors, and those behaviors are ... a research fellow at the Framingham Heart Study, Boston University ...
(Date:11/21/2014)... (HealthDay News) -- Some people with cochlear implants experience ... when they undergo an MRI scan, a new study ... researchers, about 300,000 people worldwide have cochlear implants, devices ... are deaf or have severe hearing loss. There have ... implants when undergoing MRI. One expert said the ...
(Date:11/21/2014)... HealthDay Reporter THURSDAY, Nov. 20, 2014 (HealthDay ... rules that will make it easier for everyone to know ... The proposed changes would expand the number of trials that ... -- a publicly accessible database, according to the U.S. National ... and Human Services. "This proposed rule would close ...
(Date:11/21/2014)... THURSDAY, Nov. 20, 2014 (HealthDay News) -- Kidney donation ... do for another. And now a new study finds that ... life are benefiting from policies that give them priority on ... almost 6,300 of the 16,900 kidney transplants that took place ... supplied by the study researchers. At the time ...
Breaking Medicine News(10 mins):Health News:M3 Global Research Announces Leadership Team Promotions in US and EU 2Health News:Kids Born to Overweight Moms May Face Higher Heart Risks as Adults 2Health News:MRI Can Be Painful, Disruptive for People With Cochlear Implants 2Health News:U.S. Proposes Greater Public Access to Data From Clinical Trials 2Health News:Study Supports Giving Kidney Donors Priority When They Need a Kidney 2
... LifeCare Holdings, Inc. (the,"Company") today announced its operating results ... Our net patient service revenue increased by $6.4 million, ... $88.8 million from $82.4 million,for the comparable period in 2007. ... than the same period in 2007., The increase in ...
... Patient safety in hospitals focus of 48 NQF-endorsed ... patient,safety remains a major hurdle in the United ... voluntary consensus standards focused on,measuring the performance of ... readmission, and prevention and care,of venous thromboembolism., ...
... - QLT Inc. (NASDAQ: QLTI; TSX:,QLT) announced today that ... the land and building comprising its corporate headquarters and ... with the closing of the transaction, QLT will enter ... continue its operations., "We are very pleased that ...
... appear to help quality of life for lung cancer ... -- Adding chemotherapy to other treatments being giving to ... asbestos exposure, does not appear to improve either survival ... which is usually fatal, is a cancer of the ...
... Corporation,("Select") today announced results for its first quarter ... ended March 31, 2008, net operating revenues,increased 17.4% ... the same,quarter, prior year. Income from operations decreased ... the same quarter, prior year. Net income,decreased 47.9% ...
... Governor Paterson,s leadership in proposing prescription,drug marketing reform ... AARP strongly believes,New York has a paramount interest ... address the undue influence that,pharmaceutical companies have over ... but the treatment they receive., The reforms ...
Cached Medicine News:Health News:LifeCare Holdings, Inc. Announces First Quarter Results 2Health News:LifeCare Holdings, Inc. Announces First Quarter Results 3Health News:LifeCare Holdings, Inc. Announces First Quarter Results 4Health News:LifeCare Holdings, Inc. Announces First Quarter Results 5Health News:LifeCare Holdings, Inc. Announces First Quarter Results 6Health News:LifeCare Holdings, Inc. Announces First Quarter Results 7Health News:LifeCare Holdings, Inc. Announces First Quarter Results 8Health News:LifeCare Holdings, Inc. Announces First Quarter Results 9Health News:National Quality Forum Endorses Consensus Standards for Quality of Hospital Care 2Health News:National Quality Forum Endorses Consensus Standards for Quality of Hospital Care 3Health News:National Quality Forum Endorses Consensus Standards for Quality of Hospital Care 4Health News:National Quality Forum Endorses Consensus Standards for Quality of Hospital Care 5Health News:QLT Inc. announces agreement for sale of real estate 2Health News:QLT Inc. announces agreement for sale of real estate 3Health News:Chemo for Mesothelioma Offers Limited Survival Benefits 2Health News:Select Medical Corporation Announces Results for First Quarter Ended March 31, 2008 2Health News:Select Medical Corporation Announces Results for First Quarter Ended March 31, 2008 3Health News:Select Medical Corporation Announces Results for First Quarter Ended March 31, 2008 4Health News:Select Medical Corporation Announces Results for First Quarter Ended March 31, 2008 5Health News:Select Medical Corporation Announces Results for First Quarter Ended March 31, 2008 6Health News:Select Medical Corporation Announces Results for First Quarter Ended March 31, 2008 7Health News:Select Medical Corporation Announces Results for First Quarter Ended March 31, 2008 8Health News:Select Medical Corporation Announces Results for First Quarter Ended March 31, 2008 9Health News:AARP Statement on Governor's Bill for Prescription Drug Marketing Reform and Transparency 2
... The Anti-HCV Low Titer Performance Panel ... from weak to strong positive for antibodies ... is intended for use by manufacturers and ... Comprehensive data from all major test systems ...
... The Anti-HCV Mixed Titer Performance Panel ... from weak to strong positive for antibodies ... is intended for use by diagnostic manufacturers ... and RNA assays. Comprehensive data from all ...
... POPmesh is a ... that can be used ... pelvic floor procedures, including ... prolapse. Supple yet strong, ...
Suspend® Tutoplast® Processed Fascia Lata is your naturally safe and strong choice for pelvic floor reconstruction. Suspend comes from a dense matrix of collagen bundles and transverse fasc...
Medicine Products: